OBJECTIVE: Focal cortical dysplasia (FCD) is currently recognized as the most common cause of neocortical pharmacoresistant epilepsy. Epilepsy surgery has become an increasingly successful treatment option. Herein, the largest patient cohort reported to date is analyzed regarding long-term outcome and factors relevant for long-term seizure control. METHODS: Two hundred eleven children and adults undergoing epilepsy surgery for histologically proven FCD and a follow-up period of 2-12 years were analyzed regarding the longitudinal course of seizure control, effects of FCD type, localization, magnetic resonance imaging (MRI), timing of surgery, and postoperative antiepileptic treatment. RESULTS: After 1 year, Engel class I outcome was achieved in 65% of patients and the percentage of seizure-free patients remained stable over the following (up to 12) years. Complete resection of the assumed epileptogenic area, lower age at surgery, and unilobar localization were positive prognostic indicators of long-term seizure freedom. Seizure recurrence was 12% after the first year, whereas 8% achieved late seizure freedom either following additional introduction of antiepileptic drugs (AEDs) (4%), a reoperation (2%), or a running down phenomenon (2%). Thirty-nine percent of patients had a reduction of AED from polytherapy to monotherapy or a complete cessation of AED treatment. Late seizure relapse was seen in nine patients during reduction of AEDs (i.e., in 12% of all patients with AED tapering); in four of them seizures persisted after reestablishment of antiepileptic medication. SIGNIFICANCE: Postoperative long-term seizure outcome was favorable in patients with FCD and remained stable in 80% of patients after the first postoperative year. Several preoperative factors revealed to be predictive for the postoperative outcome and may help in the preoperative counseling of patients with FCD and in the selection of ideal candidates for epilepsy surgery. Wiley Periodicals, Inc.
OBJECTIVE:Focal cortical dysplasia (FCD) is currently recognized as the most common cause of neocortical pharmacoresistant epilepsy. Epilepsy surgery has become an increasingly successful treatment option. Herein, the largest patient cohort reported to date is analyzed regarding long-term outcome and factors relevant for long-term seizure control. METHODS: Two hundred eleven children and adults undergoing epilepsy surgery for histologically proven FCD and a follow-up period of 2-12 years were analyzed regarding the longitudinal course of seizure control, effects of FCD type, localization, magnetic resonance imaging (MRI), timing of surgery, and postoperative antiepileptic treatment. RESULTS: After 1 year, Engel class I outcome was achieved in 65% of patients and the percentage of seizure-freepatients remained stable over the following (up to 12) years. Complete resection of the assumed epileptogenic area, lower age at surgery, and unilobar localization were positive prognostic indicators of long-term seizure freedom. Seizure recurrence was 12% after the first year, whereas 8% achieved late seizure freedom either following additional introduction of antiepileptic drugs (AEDs) (4%), a reoperation (2%), or a running down phenomenon (2%). Thirty-nine percent of patients had a reduction of AED from polytherapy to monotherapy or a complete cessation of AED treatment. Late seizure relapse was seen in nine patients during reduction of AEDs (i.e., in 12% of all patients with AED tapering); in four of them seizures persisted after reestablishment of antiepileptic medication. SIGNIFICANCE: Postoperative long-term seizure outcome was favorable in patients with FCD and remained stable in 80% of patients after the first postoperative year. Several preoperative factors revealed to be predictive for the postoperative outcome and may help in the preoperative counseling of patients with FCD and in the selection of ideal candidates for epilepsy surgery. Wiley Periodicals, Inc.
Authors: David W Roberts; Jaime J Bravo; Jonathan D Olson; William F Hickey; Brent T Harris; Lananh N Nguyen; Jennifer Hong; Linton T Evans; Xiaoyao Fan; Dennis Wirth; Brian C Wilson; Keith D Paulsen Journal: Oper Neurosurg (Hagerstown) Date: 2019-04-01 Impact factor: 2.703
Authors: Jessica Falco-Walter; Christian Owen; Mishu Sharma; Christopher Reggi; Mandy Yu; Travis R Stoub; Michael A Stein Journal: Neurotherapeutics Date: 2017-01 Impact factor: 7.620
Authors: S Jayalakshmi; S K Nanda; S Vooturi; R Vadapalli; P Sudhakar; S Madigubba; M Panigrahi Journal: AJNR Am J Neuroradiol Date: 2019-04-18 Impact factor: 3.825
Authors: Anna Mrelashvili; Robert J Witte; Elaine C Wirrell; Katherine C Nickels; Lily C Wong-Kisiel Journal: Pediatr Neurol Date: 2015-09-12 Impact factor: 3.372
Authors: Matthew F Sacino; Sean S Huang; Robert F Keating; William D Gaillard; Chima O Oluigbo Journal: Childs Nerv Syst Date: 2017-11-20 Impact factor: 1.475
Authors: Max O Krucoff; Alvin Y Chan; Stephen C Harward; Shervin Rahimpour; John D Rolston; Carrie Muh; Dario J Englot Journal: Epilepsia Date: 2017-10-10 Impact factor: 5.864
Authors: Rupa Radhakrishnan; James L Leach; Francesco T Mangano; Michael J Gelfand; Leonid Rozhkov; Lili Miles; Hansel M Greiner Journal: Pediatr Radiol Date: 2016-04-25
Authors: Matthew F Sacino; Cheng-Ying Ho; Matthew T Whitehead; Tesfaye Zelleke; Suresh N Magge; John Myseros; Robert F Keating; William D Gaillard; Chima O Oluigbo Journal: Childs Nerv Syst Date: 2016-04-05 Impact factor: 1.475